POLYMYALGIA RHEUMATICA
https://doi.org/10.14412/1995-4484-2018-215-227
Abstract
The lecture presents an update on the epidemiology, pathogenesis, clinical manifestations, diagnosis, differential diagnosis, and treatment stages of polymyalgia rheumatica, a chronic inflammatory disease of unknown etiology, which affects older people.
----
Authors of the article «Rheumatic polimyalgia», published in the section «Program of continuous post-graduate education of therapists» in journal «Scientific-practical rheumatology» No 2 (V 56)2018 Satybaldyev А.M et al. present their apologies for unpremeditated using for educational purposes of illustrative material on page 217 (Fig. 1) from the article by BlockmansD. Positronemission tomography and magnetic resonance imaging. In: Polymyalgia Rheumatica and Giant Cell Arteritis, Chapter 8.OxfordUniversity press. EdBh. DasguptaandCh. Dejaco; 2016:63-71 and on page 220 (Fig 2) from the article by M. Jiang,S. Navanathan“Crowned dens syndrome: a rare cause of neck pain and fever”Med J Aust 2017; 206 (5):199 || http://doi.org/10.5694/mja16.01077 Published online: 20 March 2017.
About the Authors
A. M. Satybaldyev
V.A.Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
AzamatSatybaldyev.
34A, Kashirskoe Shosse, Moscow 115522
N. V. Demidova
V.A.Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
N. M. Savushkina
V.A.Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. V. Gordeev
V.A.Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc. 2006;81:1071-83. doi: 10.4065/81.8.1071
2. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 2004;33:289-93. doi: 10.1016/j.semarthrit.2003.09.007
3. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234-45. doi: 10.1016/S0140-6736(08)61077-6
4. Muller S, Hider SL, Belcher J, et al. Is cancer assotiated with polymyalgia rheumatica? A cohort study in General Practice Research Database. Ann Rheum Dis. 2014;73:1769-73. doi: 10.1136/annrheumdis-2013-203465
5. Schnabel A, Holl-Urich K, Dalhoff K, et al. Efficacy oftransbronchial biopsy in pulmonary vasculitides. Europ Respir J. 1977;10(12):2738-43. doi: 10.1183/09031936.97.10122738
6. De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-80.
7. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis risks and relation to cyclophosphamide. Ann Intern Med. 1996;124(5):477-84. doi: 10.7326/0003-4819-124-5-199603010-00003
8. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: Long term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021-42. doi: 10.1002/15290131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J
9. Ognibene FP, Shelhamer JH, Hofman GS, et al Pneumocystis carinii pneumonia maior complication in immunosuppressive therapy in patients with Wegener’s granulomatosis. Amer J Respir Crit Care Med. 1995;151(3 pt 1):795-9.
10. Kermani ТА, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41:866-71. doi: 10.1016/j.semarthrit.2011.10.005
11. O’Neill L, Rooney P, Molloy D, et al. Regulation of inflammation and angiogenesis in giant cell arteritis by acute-phase serum amyloid A. Arthritis Rheum. 2015;67:2447-56. doi: 10.1002/art.39217
12. Weyand CM, Schonberger J, Oppitz U, et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med. 1994;179:951-60. doi: 10.1084/jem.179.3.951
13. Samson M, Audia S, Fraszczak J, et al. Thl and Thl7 lymphocytes expressing CD 161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64:3788-98. doi: 10.1002/art.34647
14. Avdeeva AS, Rubtsov YuP, Dyikanov DT, Nasonov EL. The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):442-55 (In Russ.). doi: 10.14412/1995-44842016-442-455
15. Komatsu N, Okamoto К, Sawa S, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20:62-8. doi: 10.1038/nm.3432
16. Miyabe C, Miyabe Y, Strle K, et al. An expanded population of pathogenic regulatoty T cells in giant cell arteitis is abrogayed by IL-6 blockade therapy Ann Rheum Dis. 2016. doi: 10.1136/annrheumdis-2016-2100701
17. Weyand CM, Hicok K, Hunder G, et al. Tissue cytokine patterns in patients with polymyalgia rheumatic and giant cell arteritis. Ann Int Med. 1994;121:484-91. doi: 10.7326/0003-4819-121-7199410010-00003
18. Emilie D, Liozon E, Crevon MC, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol. 1994;39:1724. doi: 10.1016/0198-8859(94)90096-5
19. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456-8. doi: 10.1093/rheumatology/29.6.456
20. Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-94. doi: 10.1002/art.1780360913
21. Caplanne D, Le Parc JM, Alexandre JA. Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis. 1996;55:403-4. doi: 10.1136/ard.55.6.403-b
22. Martinez-Taboada VM, Alvarez L, RuizSoto M, et al. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine. 2008;44:207-20. doi: 10.1016/j.cyto.2008.09.004
23. Corrigall VM, Dolan A, Dasgupta B, Panayi G. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol. 1997;36:976-80. doi: 10.1093/rheumatology/36.9.976
24. Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol. 1998;37:766-9. doi: 10.1093/rheumatology/37.7.766
25. Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis. 2010;69:263-9. doi: 10.1136/ard.2008.103663
26. Van der Geest KS, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology. 2015;54:1397-402. doi: 10.1093/rheumatology/keu526
27. Salvarani C, Pipitone N, Versari A, Hunder GG. Clinical features of polymyalgia rheumatic and giant cell arteritis. Nat Rev Rheumatol. 2012;8:509-21. doi: 10.1038/nrrheum.2012.97
28. Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford). 2012;51:77-86. doi: 10.1093/rheumatology/keq450
29. Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis. 2008;67:758-61. doi: 10.1136/ard.2007.084723
30. Chou CT, Schumacher HR Jr. Clinical and pathologic studies of synovitis polymyalgia rheumatic. Arthritis Rheum. 1984;27:110717. doi: 10.1002/art.1780271005
31. Salvarani C, Cantini F, Oliviery I, Hunder GS. Polymyalgia rheumatic: A disorder of extraarticular synovial structures? Rheumatology. 1999;26:517-21.
32. Kermani TA, Warrington KJ. Polymyalgia rheumatic. Lancet. 2013;381:63-72. doi: 10.1016/S0140-6736(12)60680-1
33. Masson C, Gonzales-Gay MA. Polymyalgia rheumatic and giant cell arteritis. In: Bijlsma JWJ, Hachulla E, eds. EULAR textbook on rheumatic diseasis. 2nd ed. London: BMJ Publishing Group; 2015. P. 754-78.
34. Gonzales-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, et al. The spectrum of polymyalgia rheumatic in northwestern Spain: incidence and analysis of variable associated with relapse in a 10 year study. J Rheumatol. 1999;26:1326-32.
35. Yates M, Graham K, Watts RA, MacGregor AJ. The prevalence of giant cell arteritis and polymyalgia rheumatic in UK primary care population. BMC Musculoscelet Disord. 2016;17:285. doi: 10.1186/s12891-016-1127-3
36. Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum. 1998;41:1221-6. doi: 10.1002/1529-0131(199807)41:7<1221::AIDART12>3.0.CO;2-W
37. Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatic can be distinquished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology. 2009;48:123-7. doi: 10.1093/rheumatology/ken343
38. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484-92. doi: 10.1136/annrheumdis-2011-200329
39. Gonzales-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol. 1999;17:276-8.
40. Gonzales-Gay MA, Garsia-Porrua C, Vasquez-Caruncho M. Polymyalgia rheumatic in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatic. J Rheumatol. 1998;25:1750-5.
41. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatic: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97:672-80. doi: 10.7326/0003-4819-97-5-672
42. Hunder GG. Giant cell arteritis and polymyalgia rheumatic. Med Clin North Am. 1997;81:195-219. doi: 10.1016/S0025-7125(05)70511-3
43. Bird HA, Leeb BF, Montecucco CM, et al. European collaborating PMR group. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatic. Ann Rheum Dis. 2005;64:626-9. doi: 10.1136/ard.2004.025296
44. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations, useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol. 2003;21(Suppl 32):S23-8.
45. Pipitone N, Salvarani C. Update on polymyalgia rheumatic. Eur J Intern Med. 2013;24:583-9. doi: 10.1016/j.ejim.2013.03.003
46. Salvarani C, Barozzi L, Boiardi L, et al. Lumbar interspinous bursitis in active polymyalgia rheumatic. Clin Exp Rheumatol. 2013;31:526-31.
47. Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imagine study. Ann Rheum Dis. 1999;58:230-6. doi: 10.1136/ard.58.4.230
48. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63:1279-83. doi: 10.1136/ard.2003.011379
49. Korkmas C, Yildiz P. Giant cell arteritis, polymyalgia rheumatic and late-onset rheumatoid arthritis, can they be components of a single disease process in elderly patients? EJR. 2017 Feb. doi: 10.5152/eurjrheum2016.039
50. Camellino D, Cimmino MA. Differential diagnosis. In: Polymyalgia rheumatic and Giant cell Arteritis. Eds Bh Dasgupta, Chr Dejaco. Oxford: Oxford University Press; 2016. P. 73-8.
51. Gonzalez-Gay MA, Vasquez-Rodriguez TR, Lopez-Diaz M, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatic. Arthritis Rheum. 2009;61:1454-61. doi: 10.1002/art.24459
52. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, et al. Giant cell arteritis and polymyalgia rheumatic can be differentiated distinct patterns of HLA class II association. J Rheumatol. 1998;25:2140-5.
53. Nesher G, Breuer GS. Giant cell arteritis and polymyalgia rheumatia:2016 update. Rambam Maimonides Med J. 2016;7:e0035. doi: 10.5041/RMMJ.10262
54. Loricera J, Blanco R, Hernandez JL, et al. Use of positron emission tomography (PET) for the diagnosis of large vessel vasculitis. Rev Esp Med Nucl Imagen Mol. 2015;34:372-7. doi: 10.1016/j.remn.2015.07.002
55. Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systemic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74:1808-17. doi: 10.1136/annrheumdis-2015207578
56. Satybaldyev AM. Rheumatic polymyalgia. In: Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017. P. 205-9 (In Russ.).
57. Yates M, Watts RA, Swords F, MacGregor AJ. Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice. Clin Exp Rheumatol. 2017;35:1-2.
58. Gonzales-Gay M, Cataneda S. Managine of giant cell arteritis and polymyalgia rheumatica. Expert Opin Orphan Drugs. 2016;4:113344. doi: 10.1080/21678707.2016.1244480
59. Van der Veen M, Dinant HJ, van der Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55:218-23. doi: 10.1136/ard.55.4.218
60. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisolone plus methotrexate for polymyalgia rheumatica: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 2004;141:493-500. doi: 10.7326/0003-4819-141-7-200410050-00005
61. Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23:624-8.
62. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136-8. doi: 10.1136/ard.45.2.136
63. Aikawa NE, Pereira RM, Lage L, et al. Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clin Rheumatol. 2012;31:575-9. doi: 10.1007/s10067-0111914-z
64. Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for management of Polymyalgia Rheumatica European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2015;67:2569-80. doi: 10.1002/art.39333
65. Izumi K, Kuda H, Ushikubo M, et al. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open. 2015;1:e000162. doi: 10.1136/rmdopen-2015000162
66. Toussirot E, Martin A, Soubrier M, et al. Rapid and sustained response to tocilizumab in patients with polymyalgia rheumatica resistant or intolerant to glucocorticoids: a multicenter open-label study. J Rheumatol. 2016;43:249-51. doi: 10.3899/jrheum.150599
67. Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatic: pretreatment chatacteristics and tocilizumab therapy. Clin Rheumatol. 2016;35:1367-75. doi: 10.1007/s10067-014-2650-y
68. Macchioni P, Boiardi L, Catanoso M, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013;43:113-8. doi: 10.1016/j.semarthrit.2013.01.003
69. Ashraf FA, Anjum S, Hussaini A, Fraser A. Refractory PMR with aortitis: lifesaving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta. BMJ Case Rep. 2013 Jun 18;2013. pii: bcr2013009523
70. Hagihari K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol. 2010;37:1075-6. doi: 10.3899/jrheum.091185
71. Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol. 2013;19:400-1. doi: 10.1097/RHU.0b013e3182a6aa0e
72. Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep. 2011 Jun 30;2011. pii: bcr0420114135
73. Seitz M, Reichenbach S, Bonel H, et al. Rapid induction of remission in large vessel vasculitis by I L-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156.
74. Lally L, Forbess L, Hatziz C, Spiera R. A prospective open-label phase 11A trial of tocilizumab in the treatment of polymyalgia rheumatic. Arthritis Rheum. 2016;68:2550-4. doi: 10.1002/art.39740
75. Devauchelle-Pensec V, Berthelol JM, Corncc D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75:1506-10. doi: 10.1136/annrheumdis-2015-208742
76. Toussirot E, Regent A, Devauchelle-Pensec V, et al. Interlcukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis? RMD. 2016;31(2):e000305. doi: 10.1136/rmdopen-2016-000305
77. Kietfer P, Hinschberger O, Ciobanu E, et al. Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review. Rev Med Intern. 2014;35:56-9.
78. Vinit J, Bielefeld P, Muller G, et al. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine. 2012;79:317-8. doi: 10.1016/j.jbspin.2011.11.008
79. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873-8. doi: 10.1002/art.1780401022
80. Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum. 2007;57:279-86. doi: 10.1002/art.22548
81. Myklebust G, Wilsgaard T, Jacobsen BK, Gran JT. Causes of death in polymyalgia rheumatica. A prospective longitudinal study of 315 cases and matched population controls. Scand J Rheumatol. 2003;32:38-41. doi: 10.1080/03009740310000382
82. Warrington KJ, Jarpa EP, Crowson CS, et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res Ther. 2009;11:R50. doi: 10.1186/ar2664
83. Kang JH, Sheu JJ, Lin HC. Polymyalgia rheumatica and the risk of stroke: a three-year follow-up study. Cerebrovasc Dis. 2011;32:497-503. doi: 10.1159/000332031
84. Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart. 2016;102:383-9. doi: 10.1136/heartjnl-2015-308514
85. Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology. 2001;40:1238-42. doi: 10.1093/rheumatology/40.11.1238
86. Rizolli R, Adachi JD, Cooper C, et al. Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2012;91:225-43. doi: 10.1007/s00223-012-9630-5
87. Rizolli R, Biver B. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015;11:98-109. doi: 10.1038/nrrheum.2014.188
88. Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222-8. doi: 10.1016/j.bone.2015.03.002
Review
For citations:
Satybaldyev A.M., Demidova N.V., Savushkina N.M., Gordeev A.V. POLYMYALGIA RHEUMATICA. Rheumatology Science and Practice. 2018;56(2):215-227. (In Russ.) https://doi.org/10.14412/1995-4484-2018-215-227
Views:
1262
Email this article 